Utilizing an innovative chemical platform to defeat antimicrobial resistance
Sector: Chemical (Industrial) • Location: Sweden
Source: EU Funding & Tenders Portal
We tackle the challenges posed by the emergence of antimicrobial resistance (AMR) with a conceptually new approach. We have established a scalable chemical platform for the development of novel antibiotic resistance breakers (ARBs). Our compounds sensitize the pathogen and restore the effectiveness of standard-of-care antibiotics. By circumventing the painstaking process of discovering and develop
- Status
- Closed
- Sector
- Chemical (Industrial), Manufacturing (Industrial)
- Location
- Sweden
- Updated
- 22 Jul 2026
- Source
- EU Funding & Tenders Portal
ConstructChat
Ask ConstructChat about Utilizing an innovative chemical platform to defeat antimicrobial resistance
Pick a question to edit it, or write your own.
First answer free · no account
Project Information FAQ
Project Information
Participants
| Not available for this record. |
Status
Original status | ended |
Taiyo status | Closed |
Taiyo last update | 2026-07-22 |
Contact
| Not available for this record. |
Description
Description | We tackle the challenges posed by the emergence of antimicrobial resistance (AMR) with a conceptually new approach. We have established a scalable chemical platform for the development of novel antibiotic resistance breakers (ARBs). Our compounds sensitize the pathogen and restore the effectiveness of standard-of-care antibiotics. By circumventing the painstaking process of discovering and developing new antibiotics, we bring forth a more cost-effective approach to confront the emergence of AMR. Allowing pharmaceutical companies to protect decades worth of R&D efforts and billions of euros in development costs, we present them with an attractive value proposition. Our platform enables the fast, high-yield production of ARBs against gram-positive bacteria (GmPcides). Our compounds have displayed effectiveness against two of the most threatening drug-resistant pathogens MRSA and VRE. Moreover, the compounds exhibit a strong in vivo synergy with two of the world’s most essential antibiotics Gentamicin and Vancomycin. |
Location
Country | Sweden |
Source
Source | EU Funding & Tenders Portal |
URL |
More Details
Record type | Project |
Sector | Chemical (Industrial), Manufacturing (Industrial) |
Article published date | 2026-02-15 |
Research
Free account
View all details
You are reading the public part. A free account opens the rest:
- Every detail on this project
- News and media coverage
- Technical research
Free account · no card · lands you back on this project